



September 13, 2011

**Re: Update Regarding Supply of Cerezyme® (imiglucerase for injection)**

Dear U.S. Healthcare Provider,

We would like to provide an update regarding our expectations for supply of Cerezyme in the U.S. A temporary decrease in Cerezyme yields, combined with changes to our product release processes and procedures that lengthen the overall time it takes to release Cerezyme require us to change our supply projections for the next four months starting October, 2011. Changes to Cerezyme availability will be felt globally. Delays in shipments will likely affect patients and some adjustment to individual treatment plans may be necessary.

For the U.S. from October through January we expect to provide:

- One full dose (equivalent to the currently prescribed dose) per month for patients 19 years old and older currently treated with Cerezyme.
- Two full doses per month for patients 18 years old and younger and for Type 2/3 patients currently treated with Cerezyme.

As a reminder, most patients normally receive Cerezyme infusions at one full dose every two weeks. For patients on alternate dosing schedules, your Genzyme Representative and/or Case Manager will be able to provide detailed supply information. Genzyme will confirm shipping availability each month; please note that the timing of shipping availability may vary somewhat month to month.

Given current improvements to productivity and progress with our manufacturing recovery, we currently anticipate an improving Cerezyme supply outlook from February 2012 forward. We plan to provide an update on 2012 supply to the U.S. Gaucher community by the end of this year.

We sincerely regret this disruption to patient treatment plans. In order to support the current level of patient demand, Cerezyme is made available as it is produced, which does not allow us to build inventory. Operating with little or no inventory means changes like these in our manufacturing plans can impact supply. Over the past four years there has been significant investment in a new manufacturing facility to produce Fabrazyme® (agalsidase beta) in Framingham, MA. We are in the process of plant validation and currently anticipate completing regulatory approval processes that will allow us to ship product in the first part of 2012. This is a critical step as it will allow us to improve Cerezyme production at the Allston facility which is producing both Cerezyme and Fabrazyme today.

We remain committed to providing supply updates as new information develops and will work closely with you to minimize the impact of any supply disruption. For any questions, please contact your local Genzyme Representative, or Case Manager at 1-800-745-4447, Option 3, or Genzyme Medical Information at 1-800-745-4447, Option 2.

Sincerely,

Daniel Gruskin, MD  
Senior Director, US Medical Affairs  
Genzyme, a Sanofi Company

Rogério Vivaldi, MD  
President, Personalized Genetic Health (PGH)  
Genzyme, a Sanofi Company

*Please see accompanying full Prescribing Information*

CZ-US-P399-09-11